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BoneAbstract Aim: Risk-reducing salpingo-oophorectomy (RRSO) reduces ovarian cancer risk
in BRCA mutation carriers. RRSO is assumed to decrease bone mineral density (BMD)
and increase fracture risk more than natural menopause. We aimed to compare BMD and
fracture incidence after premenopausal RRSO to general population data and identify risk
factors for low BMD and fractures after RRSO.
Methods: In 212 women with RRSO at premenopausal age, BMD was measured by dual
energy X-ray absorptiometry. Fractures and risk factors were assessed by self-administered
questionnaire. Fracture incidence after RRSO was compared to general practitioner data
by using standardised incidence ratios (SIRs). Risk factors for low standardised BMD-scores
and fractures were identified by regression analyses.en, The
umcg.
umcg.nl
I.E. Fakkert et al. / European Journal of Cancer 51 (2015) 400–408 401Results: Median age at RRSO was 42 years (range 35–65) and duration of follow-up 5 years
(2–8). Standardised lumbar spine (Z = 0.01, p = 0.870) and femoral neck BMD (Z = 0.15,
p = 0.019) were not lower than population BMD. Higher age at time of RRSO and use of hor-
monal replacement therapy were associated with higher, and current smoking with lower
standardised BMD-scores. Sixteen women reported 22 fractures. Fracture incidence was not
higher than expected from the general population (all fractures: 25–44 years: SIR 2.12 [95%
confidence interval (CI) 0.85–4.37]; 45–64 years: SIR 1.65 [95% CI 0.92–2.72]).
Conclusion: Five years after RRSO, BMD and fracture incidence were not different than
expected from the general population. Based on these data it appears safe not to intensively
screen for osteoporosis within five years after RRSO, although prospective research on the
long-term effects of RRSO on bone is warranted.
 2014 Elsevier Ltd. All rights reserved.Women with RRSO in 2009
at age 52 years: N = 2671. Introduction
Breast and ovarian cancer risk is elevated in women
with a family history of breast cancer (hereditary breast
ovarian cancer, HBOC), especially in women carrying a
germ line mutation in the BRCA1 and BRCA2 genes
[1,2]. These women often opt for risk-reducing salpingo-
oophorectomy (RRSO) to reduce ovarian cancer risk, as
ovarian cancer screening is not effective [3]. RRSO reduces
ovarian cancer risk by up to 96% [4]. RRSO is advised in
BRCA1 and BRCA2 mutation carriers at the age of 35–
40 years and 40–45 years, respectively [5]. The median
age at RRSO, which leads to acute oestrogen deprivation,
is about 10 years earlier than natural menopause [6].
When ovarian oestrogen production declines during
natural menopause, bonemineral density (BMD) decrease
accelerates and fracture incidence increases [7]. Reports on
the effect of early and surgical menopause on BMD and
fracture incidence are inconclusive. Several studies sug-
gested that BMD was lower and fracture incidence higher
after early natural and surgical menopause, than after nat-
ural menopause at normal age [8,9]. Others found a tran-
sient effect on fracture incidence or no effect at all [10,11].
Several studies reported a high risk of osteoporosis after
RRSO; however, these studies were all prone to bias, due
to retrospective study designs, selected study populations
and in some cases lack of a control group [12–15].
This study aimed to compare BMD and fracture inci-
dence after RRSObeforemenopausal age in an unselected
consecutive series of BRCA1/2 mutation carriers and
women with a family history of breast and ovarian cancer,
to what can be expected from the general female popula-
tion. The secondary aim was to identify risk factors for
low BMD and fracture incidence after RRSO.Deceased: N=10
Malignancy at RRSO: N=3




Women attending osteoporosis 
and fracture screening: N=212
Fig. 1. Flowchart on the recruitment and enrolment of participants
eligible for osteoporosis and fracture screening after RRSO.
Abbreviations: RRSO is risk-reducing salpingo-oophorectomy.2. Patients and methods
2.1. Study population and protocol
Since 1994 all women visiting the family cancer clinic
at the University Medical Center Groningen are
registered in a prospective database [16]. BetweenFebruary 2011 and May 2012, all BRCA1/2 mutation
carriers and women with a positive family history of
breast and ovarian cancer with RRSO at the age of
652 were invited to attend osteoporosis and fracture
screening if they werePtwo years after RRSO. Women
in whom ovarian cancer was detected at RRSO were
excluded. Of the 254 invited women, 212 attended and
gave written informed consent for the study (Fig. 1).
Women were evaluated by a researcher, under super-
vision of a medical doctor, according to a standard pro-
tocol which included measurement of height, weight, a
self-administered questionnaire, collection of blood
samples and BMD measurement. The institutional eth-
ics review board considered this study extended stan-
dard care.2.2. BMD measurement
BMD of the lumbar spine (LS; anterior-posterior
projection at L1–L4) and femoral neck (FN) were mea-
sured by dual energy X-ray absorptiometry (DXA)
using a Hologic Discovery A densitometer (Hologic
Inc., Bedford, MA). Vertebral fracture assessment
(VFA) was performed with the same DXA machine,
as previously described [17].
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The questionnaire aimed at identifying history of
bone fractures and risk factors for osteoporosis and
low BMD. It was based on the clinical questionnaire
used at the fracture and osteoporosis outpatient clinic
at our centre [18]. The questionnaire was sent to the
patients before their osteoporosis and fracture screening
visit. During the visit, missing or inconsistent answers
were discussed by the researcher and the patient and
corrected by the researcher if appropriate.2.4. Laboratory assessments
A non-fasting blood sample was collected between
9:00 a.m. and 4:30 p.m. Calcium and albumin were mea-
sured by colorimetric assay (Roche Modular P, Mann-
heim, Germany; inter-assay coefficient of variation
(IA–CV) < 2.0% and <1.8%; lower detection limit
0.05 mmol/L and 10 g/L for calcium and albumin,
respectively). Calcium was corrected for albumin levels
with the following formula: Corrected calcium (mmol/
L) = measured total calcium (mmol/L) + 0.02
(41  serum albumin [g/L]). Serum 25(OH)D3 was mea-
sured by isotope dilution–online solid phase extraction
liquid chromatography–tandem mass spectrometry
[19]. Method specifications were: level of quantification
4.0 nmol/L; IA-CV <14.1%; recovery 93–98%; linearity
r2 = 0.9972. Accuracy was secured by the use of refer-
ence material from the National Institute of Standards
& Technology (Gaithersburg, MD).2.5. Study end-points
Results of BMD measurement were expressed as
BMD in g/cm2 and standardised by using Z- and
T-scores. Z-scores present the number of standard devi-
ations (SD) from the mean bone mineral density in
woman of the same age [20,21]. T-scores present the
number of SDs from the mean peak BMD as reached
in women between 20 and 30 years of age [20,21].
According to the World Health Organisation definition,
‘osteoporosis’ is defined as a T-score of 62.5; ‘osteop-
aenia’ as a T-score between 2.5 and 1.0; and ‘normal’
as a T-score P1.0.
Fracture incidence after RRSO was evaluated by
questionnaire. Fractures that were impossible based on
clinical data were excluded. Aetiology of fractures was
assessed to determine if they were fragility fractures,
i.e. caused by low energy trauma. Low energy trauma
was defined as a fall from standing position or a height
of one metre or less [18].
To identify the prevalence of occult vertebral frac-
tures, VFA data were used. Vertebral-shape deformities
were classified using the Genant classification (grade 0:
no deformities; grade 1: mild deformity, 20–25% heightdecrease; grade 2: moderate deformity, 25–40% height
decrease; and grade 3: severe deformity, >40% height
decrease) [22]. In patients with a relative height reduc-
tion of any vertebra of P20% on VFA and no known
previous vertebral fracture at that site, an X-ray of the
thoracic and lumbar spine was made for further evalua-
tion. According to the Dutch guidelines, a vertebral
fracture was defined as a height reduction of >25% on
lateral X-ray of the spine or of >40% on VFA scans [23].2.6. Reference population
The standard Hologic reference databases for Cauca-
sian women were used to calculate Z- and T-scores
[20,21]. For femoral neck references, data were retrieved
from NHANES III [20]. For lumbar spine, data were
retrieved from a Hologic study on BMD in healthy
American women [21].
Age-specific fracture incidence in Dutch women was
obtained from a national survey on disease incidence
in four general practices [24].2.7. Statistical analysis
Analyses were conducted using IBM SPSS Statistics
version 20 (IBM Corporation, Armonk, NY, United
States of America (USA)). p-Values <0.05 were consid-
ered significant. Descriptive statistics were used to pres-
ent patient characteristics using mean ± SD for
parametric, median (range) for non-parametric and
number (%) for dichotomous data.
To compare BMD in the study population to the ref-
erence population, mean BMD Z-scores for the total
group were compared to the mean Z-score in a healthy
reference population (i.e. Z = 0, SD = 1) by using
unpaired one-sample t-test.
Fracture incidence after RRSO was compared to age-
specific fracture incidence in the Dutch female popula-
tion by using standardised incidence ratios (SIRs). SIRs
were calculated for first and all incident fractures after
RRSO.
Multiple imputation was applied to impute missing
values for: BMD LS Z-score (N = 1), long term use of
glucocorticosteroids (i.e. 7.5 mg prednisolone or equiva-
lent P3 months; N = 1), corrected serum calcium
(N = 2) and serum 25(OH)D3 (N = 1), using all vari-
ables included in the regression models. Ten imputed
datasets were used in the regression analyses and results
were combined according to Rubin’s rules [25].
Factors associated with BMD LS and FN Z-score
were identified using linear univariate regression analy-
ses. Factors individually characterising the women
who developed incident fractures after RRSO were iden-
tified using univariate logistic regression analysis. For
the univariate analysis we selected factors from the ques-
tionnaire associated with breast cancer and clinical risk
Table 1
Demographics and main clinical features of the study population (N = 212).
Basic characteristics M M
Age in years 49 (36–65) 0 Ever use calcium supplement 63 (30) 0
Age at RRSO in years 42 (30–52) 0 Current use 46 (22)
Follow-up in years 5 (2–25) 0 Ever use vitamin D3 supplement 61 (29) 0
BMI in kg/m2 26 (18–54) 0 Current use 49 (23)
Menopausal status before RRSO 0 Smoking – current 41 (19) 0
Premenopausal 177 (84) Alcohol consumption in units/week 2 (0–35) 0
Regularly menstruating 94 (44) 67 units/week 174 (82)
Irregularly menstruating 29 (14) >7 units/week 38 (18)
OCP use 54 (26) Long-term use GCSa 8 (4) 1
Postmenopausal 27 (13) Oncologic characteristics
Natural 11 (5) History of breast cancer 80 (38) 0
Chemotherapy induced 16 (8) Chemotherapy 60 (28) 0
Unknown: Hysterectomy 8 (4) Ever use AI 11 (5) 0
Fracture before RRSO 64 (30) 0 Ever use tamoxifen 17 (8) 0
Parent with hip fracture 5 (2) Mutation status 0
Ever use AOD 18 (9) 0 BRCA1 121 (57)
Current use 8 (4) BRCA2 60 (28)
Indication AOD 0 HBOC 31 (15)
AI use 3 (1) Ever use HT 100 (47) 0
GCS use 2 (1) Current use HT 51 (24) 0
Prevention 3 (1) Lab
Osteoporosis 3 (1) Corrected serum calcium in mmol/Lb 2.3 (2.0–2.5) 2
Osteopaenia 5 (2) Serum 25(OH)D3 in nmol/L 64 (16–151) 1
Fracture after RRSO 2 (1)
Values are median (range) and No. (%); M is missing, RRSO is risk-reducing salpingo-oophorectomy, BMI is body mass index, AI is aromatase
inhibitor, HBOC is hereditary breast ovarian cancer, HT is hormonal replacement therapy, GCS is glucocorticosteroid, AOD is anti-osteoporotic
drugs.
a Use of prednisone 7.5 mg or equivalent >3 months or >3 oral prednisolone courses per years.
b Calcium was corrected for albumin levels with the following formula: Corrected calcium (mmol/L) = measured total Calcium (mmol/L) + 0.02
(41  serum albumin [g/L]).
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[18,26]. Multivariate regression analyses were performed
with conditional stepwise backward inclusion of those
variables with a p-value <0.250 in univariate analysis.
Multivariate analyses were corrected for ever use of
anti-osteoporotic drugs (AOD) and calcium and vitamin
D3 supplementation. Because fracture incidence was
measured retrospectively, while questionnaire items
and BMD were measured cross-sectionally, we analysed
risk factors that we assumed to be constant for a longer
period of time, such as ever smoking, but not current
smoking.3. Results
3.1. Study population
In a total of 212 women, median age at RRSO was
42 years (range 30–52) and median current age was
49 years (36–65; Table 1). Follow-up time from RRSO
to screening was 5 years (2–25). Of the 18 (9%) women
who reported the use of anti-osteoporotic drugs after
RRSO, eight were using these drugs at the time of
screening. Indications for AOD use are described in
Table 1.3.2. Bone mineral density
BMD LS and FN Z-scores were not lower than Z = 0
(mean Z score 0.01 ± 1.09, p = 0.870 and mean Z-score
0.15 ± 0.93, p = 0.019, respectively; Table 2). Of all
patients 6% (n = 13) had osteoporosis according to
T-score, 12 of the lumbar spine and one of the femoral
neck. Mean Z-scores for women with osteoporosis were
1.8 ± 0.44 and 0.08 ± 0.55 for lumbar spine and
femoral neck respectively. Osteoporosis incidence was
9.2/1000 women-years.
In the multivariate linear regression model, older age
at RRSO, higher BMI and current hormonal replace-
ment therapy (HT) use were positively associated with
BMD LS Z-score, while no covariates were significantly
negatively associated (Table 3). For BMD FN Z-score,
longer duration of follow-up, higher BMI and ever use
of HT were positively associated, while current smoking
was negatively associated (Table 3).3.3. Incident fractures
Seventeen (8%) women reported 23 fractures after
RRSO. One fracture was excluded, as clinical data
described a cartilage defect, but not a bone defect. Of
Table 2
Bone mineral density and fracture incidence after RRSO.
Bone mineral density
Lumbar spine (N = 211)a Femoral neck (N = 212)
BMD in g/cm2b 0.97 ± 0.12 0.79 ± 0.11
Z-score – total study population 0.01 ± 1.09 0.15 ± 0.93*
Women with history of breast cancer 0.02 ± 1.00 0.011 ± 0.87
Women without history of breast cancer 0.03 ± 2.24 0.18 ± 0.039*
Women with age 652 years 0.02 ± 1.07 0.11 ± 0.93
Women with age >52 years 0.09 ± 1.13 0.24 ± 0.94*
T-score 0.72 ± 1.11 0.6 ± 0.96
Osteoporosis 13 (6)
Osteopaenia 89 (42)
Normal BMD 110 (52)
Fractures
Questionnaire VFA (N = 206)
Women with fracture 16 (8) Other fractures 17 Height reduction >20% 12 (6)
No. of fractures 22 Clavicle 2 Known abnormalities 5
Fragility fracturesc 19 Elbow 4 VF before RRSO 1
Vertebral 3 Pelvis 1 VF after RRSO 3
Hip – Ankle/Foot 4 Scheuermann’s disease 1
Wrist 2 Toe/finger 6 Height reduction >25% on X-ray 0
Values are mean ± SD or No. (%); RRSO is risk-reducing salpingo-oophorectomy; BMD is bone mineral density; VFA is vertebral fracture
assessment; VF is vertebral fracture; RRSO is risk-reducing salpingo-oophorectomy.
a For one woman no DXA of the lumbar spine was made because of the presence of osteosynthesis material after scoliosis surgery.
b For three women, DXA scans were performed outside the UMCG: one scan before the start of strontium ranelate therapy, one a year before
study entry and one because of logistics close to her hometown.
c Fragility fractures are fractures from a fall from standing position or a height <1 m.
* p < 0.05 with one-sample t-test.
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ered fragility fractures (Table 2). Median follow-up to
first fracture after RRSO was 5 years (1–15). Fracture
incidence after RRSO was comparable to fracture inci-
dence in the GP reference population (Table 4). In the
multivariate analysis, alcohol consumption was posi-
tively associated with the occurrence of fractures after
RRSO (Table 5).
3.4. VFA outcomes
On VFA, 12 (6%) women had 13 relative vertebral
height reductions ofP20%. The affected vertebrae were:
Th6, Th7 (N = 2), Th11 (N = 2), Th12 (N = 3), L1
(N = 3), L2 and L3. In five women, these vertebral
deformities were diagnosed before study entry and were
considered known vertebral fractures. Of the other seven
women, four had a minimal deformity and three a mod-
erate deformity according to the Genant classification
on VFA. None of these seven women had height reduc-
tions of >25% on X-ray, so none of the deformations
detected with VFA fulfilled the Dutch definition of a
vertebral fracture on X-ray [23].
3.5. Secondary causes of osteoporosis
Several women reported co-morbid diseases that may
have contributed to a higher fracture risk according to
the QFracture algorithm, either in medical history orat the time of study participation [27]. Of all women,
37% (n = 79) reported one or more co-morbid diseases,
of the women with fractures this was 41% (n = 7,
p = 0.728; table on co-morbid diseases Supplementary
Online).
4. Discussion
In an unselected consecutive series of 212 women
with RRSO at age 652, after a median follow-up of
5 years, BMD was not lower (BMD LS Z-score: 0.01,
p = 0.870 and BMD FN Z-score: 0.15, p = 0.019) and
fracture incidence was not higher (all fractures: 25–
44 years: SIR 2.12 [95% confidence interval (CI) 0.85–
4.37]; 45–64 years: SIR 1.65 [95% CI 0.92–2.72]) than
what can be expected from an age-matched reference
population.
These findings are in contrast to the common hypoth-
eses that after RRSO BMD decreases and fracture inci-
dence rises faster than after natural menopause.
However, these are in line with the results of previous
studies that failed to find an effect of early and surgical
menopause on bone mineral density and fractures
[11,28], and studies that found an effect of early or sur-
gical menopause only in the first years after the proce-
dure, which suggests that the effect of RRSO might
eventually be overruled by chronological age [10,29].
However, an effect of RRSO on BMD or fracture
risk in this study population cannot be completely
Table 3









b SE p-Value b SE p-Value b SE p-Value b SE p-Value
Age at RRSO (per
year)
0.02 0.01 0.101 0.06 0.02 0.000* 0.00 0.01 0.969
Follow-up (per
year)
0.01 0.02 0.625 0.06 0.02 0.003* 0.04 0.02 0.043*
BMI (per kg/m2) 0.04 0.01 0.004* 0.05 0.01 0.000* 0.04 0.01 0.000* 0.04 0.01 0.000*
Postmenopausal
before RRSO
0.24 0.23 0.287 0.11 0.19 0.582
Fracture before
RRSO
0.06 0.16 0.706 0.07 0.14 0.601
Parent with hip
fracture
0.97 0.49 0.047* 0.11 0.42 0.788
Smoking – current 0.23 0.19 0.234 0.54 0.16 0.001* 0.52 0.15 0.001*
Alcohol per unit/
wk
0.01 0.01 0.326 0.01 0.01 0.655
Alcohol >7 units/
wk
0.04 0.20 0.856 0.11 0.17 0.522
Long-term use
GCSb
0.24 0.38 0.527 0.01 0.33 0.973
History of breast
cancer
0.06 0.16 0.699 0.07 0.13 0.608
Chemotherapy 0.08 0.17 0.644 0.03 0.14 0.812
Ever use of AI 0.53 0.34 0.117 0.11 0.29 0.700
Ever use of
tamoxifen
0.13 0.28 0.634 0.14 0.24 0.563
Ever use of HT 0.22 0.15 0.141 0.23 0.13 0.067 0.25 0.12 0.043*
Current use of HT 0.33 0.17 0.056 0.76 0.19 0.000* 0.12 0.15 0.417
Corrected serum
calcium
0.39 0.99 0.692 0.36 0.84 0.666
Serum 25(OH)D3 0.00 0.00 0.182 0.00 0.00 0.806
SE is standard error; RRSO is risk-reducing salpingo-oophorectomy; BMI is body mass index; AI is aromatase inhibitor; HT is hormonal
replacement therapy; GCS is glucocorticosteroids; AOD is anti-osteoporotic drugs.
a Adjusted for AOD/calcium/vitamin D3 supplement use.
b Use of prednisone 7.5 mg or equivalent >3 months or >3 oral prednisolone courses per years.
* p < 0.05.
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proportion of women had used bone protective medi-
cation, such as HT (47%), tamoxifen (8%) and AOD
(9%). This might have attenuated the effect of RRSO
on both BMD and fracture incidence. HT use was
associated with higher BMD LS and FN Z-scores in
multivariate analysis, which confirms the known pro-
tective effect of HT on BMD [30]. Secondly, a positive
relation between age at RRSO and BMD Z-score was
shown, which might indicate that BMD is lower in
women who have RRSO at younger age. Thirdly, it
is known that fracture incidence is relatively low at
young age and increases significantly with older age
[10]. A long-term effect of RRSO on fracture risk at
older age needs to be further investigated in a prospec-
tive longitudinal study. Lastly, changes in bone charac-
teristics might increase fracture risk independently of
actual BMD, such as structural changes in bone archi-
tecture and changes in bone loss rate. BMD measure-
ment by DXA might not be sensitive enough toevaluate bone architecture and detect structural
changes in bone after RRSO. It is possible that these
changes are visible on more advanced techniques like
quantitative computed tomography, which measures
cortical and trabecular BMD separately or on DXA
using trabecular bone score software [31,32]. Also, a
higher rate of bone loss has been shown to be associ-
ated with fracture risk independent of actual BMD
and a higher rate of bone loss in surgical menopause
compared to natural menopause has been reported by
others [33,34]. As BMD was measured cross-sectionally
in this study, BMD before and after RRSO could not
be compared in the same woman to calculate bone loss
rates. Bone turnover marker measurement might be
useful to estimate bone loss rate after RRSO [35].
In addition, this study has several limitations. Ques-
tionnaires were used to assess fracture incidence and risk
factors, which might have induced a risk of selective
reporting. Fracture incidence was not systematically
confirmed with hospital data. We considered a question-
Table 4
Comparison of fracture incidence observed after RRSO to fracture incidence expected after RRSO from general practitioner data using
standardised incidence ratios (SIRs).
Age in years No. of womena No. of women-years FI reference populationb Exp. Obs. SIR (95% CI)
First incident fractures
25–44 139 557.38 5.7 3.2 5 1.56 (0.50–3.65)
45–64 158 807.56 10.7 8.6 11 1.28 (0.64–2.29)
65–74 1 0.33 25 0 0 –
All incident fractures
25–44 139 570.14 5.7 3.3 7 2.12 (0.85–4.37)
45–64 160 845.34 10.7 9.1 15 1.65 (0.92–2.72)
65–74 2 1.23 25 0 0 –
RRSO is risk-reducing salpingo-oophorectomy; No. is number; FI is fracture incidence/1000 women-years; Exp. is expected number of fractures;
Obs. is observed number of fractures; SIR is standardised incidence ratio; CI is confidence interval.
a No. of women attributing to calculation of total no. of women-years per age group.
b van de Lisdonk et al. [24].
Table 5
Uni- and multivariate logistic regression analyses on women who reported fractures after RRSO.
Univariate analysis Multivariate analysisa
OR 95% CI p-Value OR 95% CI p-Value
Age (per year) 1.0 0.9–1.1 0.511
Age at RRSO (per year) 1.0 0.9–1.1 0.668
Duration of follow-up (per year) 1.1 1.0–1.3 0.051
BMI (per kg/m2) 1.0 0.9–1.1 0.847
Postmenopausal before RRSO 0.4 0.1–3.3 0.405
Fracture before RRSO 1.1 0.4–3.2 0.923
Parent with hip fracture – – –
Ever smoking 0.5 0.2–1.3 0.130
Alcohol (per unit/week) 1.1 1.0–1.1 0.179*
Alcohol >7 units/week 3.1 1.0–9.1 0.042* 3.1 1.0–9.2 0.014*
Long-term use GCSb 1.7 0.2–14.5 0.638
History of breast cancer 1.7 0.6–4.8 0.297
Chemotherapy 1.6 0.5–4.6 0.399
Ever use of AI 1.2 0.1–10.4 0.842
Ever use of tamoxifen 1.7 0.4–8.3 0.497
Ever use of HT 0.7 0.2–1.9 0.423
Z-score BMD lumbar spine 1.0 0.6–1.6 0.993
Z-score BMD femoral neck 1.0 0.6–1.7 0.974
Corrected serum calcium 1.6 0.0–1167.0 0.896
Serum 25(OH)D3 1.0 1.0–1.0 0.892
CI is confidence interval; RRSO is risk-reducing salpingo-oophorectomy; BMI is body mass index; AI is aromatase inhibitor; HT is hormonal
replacement therapy; GCS is glucocorticosteroids; BMD is bone mineral density; AOD is anti-osteoporotic drugs.
a Adjusted for AOD/calcium/vitamin D3 supplement use.
b Use of prednisone 7.5 mg or equivalent >3 months or >3 oral prednisolone courses per years.
* p < 0.05.
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ical confirmation was available for 16/22 fractures,
which might be considered a limitation.
Fracture incidence in the control population was
assessed trough general practitioner (GP) reports, which
might have resulted in under reporting of the actual
fracture risk, as some fractures are directly seen at the
emergency department. However, as almost all Dutch
citizens are registered with a GP who records all their
diagnoses, and because GPs function as the gatekeepers
for specialised medical care, one can assume that GPs
have the most complete file on the incidence of healthproblems in the general population. Moreover, within
this study, GPs are trained for adequately registering
health problems and quality of the registration was
monitored [24]. This was further supported by the find-
ing that fracture incidence before RRSO was compara-
ble to fracture incidence in the reference population
(Supplementary table online).
To our knowledge, this study is the largest study on
the effects of RRSO at premenopausal age on bone
mineral density and fracture incidence. Participation
rate was as high as 83%. Also, we are the first to mea-
sure BMD after RRSO in an unselected consecutive
I.E. Fakkert et al. / European Journal of Cancer 51 (2015) 400–408 407series of women with RRSO, which makes this study
population representative for actual practice without
selection bias.
In this study, women with RRSO at premenopausal
age did not have lower BMD and higher fracture inci-
dences compared to an age-matched control population.
Based on these results, it cannot be advised to offer
BMD measurements to all women after RRSO.
Prospective research remains warranted to evaluate
long-term fracture incidence after RRSO.
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